Tesaro Garners $101,000,000 Series B Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ae77edee-f1ae-427c-a5a8-1283f02e917a&Preview=1 -
Date
6/21/2011 -
Company Name
Tesaro -
Mailing Address
135 Clarendon St. Boston, MA 02116 -
Company Description
TESARO is a privately held oncology-focused biopharmaceutical company whose passionate associates are dedicated to improving the lives of cancer patients by developing and providing safer and more effective therapeutics and supportive care products. -
Website
http://www.tesarobio.com -
Transaction Type
Venture Equity -
Transaction Amount
$101,000,000 -
Transaction Round
Series B -
Proceeds Purposes
TESARO plans to develop one or more compounds for oncology indications, including the treatment of patients with non-small cell lung cancer (NSCLC) whose tumors express an ALK fusion protein; recent clinical proof-of-concept has been demonstrated for ALK inhibition in this patient population. The Series B financing will fund further development of these programs and expansion of the pipeline. -
M&A Terms
-
Venture Investor
Kleiner Perkins Caufield & Byers -
Venture Investor
InterWest Partners -
Venture Investor
New Enterprise Associates -
Venture Investor
New Enterprise Associates -
Venture Investor
Pappas Ventures -
Venture Investor
Deerfield Capital -
Venture Investor
Undisclosed
